PACAP-27: brain signaling peptide linked to stress, PTSD, and migraine

What this is

PACAP-27 (Pituitary Adenylate Cyclase-Activating Peptide-27) is a 27-amino-acid neuropeptide and the shorter naturally occurring form of the PACAP family. It corresponds to the N-terminal 27 residues of the full-length 38-residue peptide, PACAP-38, and shares the same core pharmacology at the PAC1 receptor (PAC1R). PACAP peptides belong to the VIP/secretin/glucagon superfamily and are found throughout the brain, pituitary, adrenal glands, and peripheral nervous system. The sequence stored here — HIDGIFTDSYSRYRKQMAVKKYLAAVL — is the chicken (avian) variant of PACAP-27; the mammalian (human, rat, ovine) sequence differs at position 2, where isoleucine is replaced by serine (HSDGIFTDSYSRYRKQMAVKKYLAAVL). The McRory 1997 work on the chicken gene that encodes both GHRH and PACAP in a single transcript is the source for this avian sequence (McRory and colleagues, DNA and Cell Biology, 1997). Both forms are C-terminally amidated in their naturally processed state — the raw sequence shown does not represent the amide modification at the C-terminus.

History

PACAP was first isolated in 1989 by Miyata, Arimura, and colleagues from ovine hypothalamic tissue — a 2,400 g extract — while screening for novel adenylate cyclase-stimulating factors in pituitary cells. The 38-residue form was identified first. In 1990, the same group isolated the shorter 27-residue N-terminal fragment from purification byproducts, reporting that it retained similar adenylate cyclase-stimulating activity and shared approximately 68% sequence identity with vasoactive intestinal peptide (VIP) (Miyata and colleagues, Biochemical and Biophysical Research Communications, 1990). The human PAC1 receptor was cloned and functionally expressed by Ogi and colleagues in 1993, establishing the molecular basis for PACAP's distinct pharmacology relative to the VIP receptors VPAC1 and VPAC2 (Ogi and colleagues, Biochemical and Biophysical Research Communications, 1993). The avian gene encoding PACAP was later found to differ from mammalian organization: in chicken, GHRH and PACAP are encoded on a single gene through alternative processing — unlike mammals where they are encoded on separate genes — making the chicken PACAP-27 a useful evolutionary reference point for studying the peptide family's origins (McRory and colleagues, 1997).

What it does

PACAP-27 activates the PAC1 receptor, a class B G protein-coupled receptor (GPCR) that is expressed at high levels in the brain, pituitary, and adrenal glands. Activation triggers a rise in intracellular cAMP, which in turn supports neuronal survival, modulates the stress response, regulates fear memory circuits, and influences pain signaling. In the context of stress biology, the PACAP–PAC1 system acts as a sensitizer: it amplifies the body's response to threatening stimuli, heightens fear recall, and is upregulated by estrogen in regions like the amygdala — a pattern that may explain sex differences in stress-related conditions. PACAP-27 also activates the VIP-shared receptors VPAC1 and VPAC2, but with lower receptor selectivity than PACAP-38; it therefore serves as a research tool for comparing partial versus full-length PACAP signaling through PAC1R. The peptide triggers vascular effects (vasodilation) consistent with its role in migraine pathogenesis, and both PACAP-27 and PACAP-38 can provoke migraine-like headache in susceptible individuals when administered intravenously.

Evidence

• Human: Elevated blood levels of PACAP38 (the longer form processed from the same precursor) are correlated with PTSD symptom severity in women; a SNP (rs2267735) in the PAC1 receptor gene (ADCYAP1R1) associates with PTSD diagnosis and fear discrimination in a female-specific manner (Ressler and colleagues, Nature, 2011). PACAP-27 and PACAP-38 are both capable of provoking migraine-like headache after intravenous infusion in people with migraine history. No registered clinical trials for PACAP-27 as a standalone therapeutic were identified on ClinicalTrials.gov; clinical interest is focused primarily on PACAP-38 and on PAC1 receptor antagonists.
• Animal: In rodent models, PACAP–PAC1R signaling in the amygdala and ventromedial hypothalamus regulates fear extinction; pharmacological disruption of PAC1R impairs cue learning in fear conditioning paradigms. Estrogen replacement increases both PACAP and PAC1R transcripts in stress-relevant brain regions, corroborating the sex-dependent associations observed in humans (King and colleagues, Stress, 2017).
• In vitro: PACAP-27 stimulates adenylate cyclase with approximately 1,000-fold greater potency than VIP. At the PAC1 receptor, structure-function studies report a binding IC50 of approximately 2.82 nM for PACAP-27, compared with ~0.28 nM for PACAP-38; both are equipotent for cAMP generation (EC50 ~0.03 nM), consistent with receptor spareness at PAC1R. PAC1R activates multiple downstream pathways beyond adenylate cyclase, including phospholipase C, MEK/ERK, and PI3K/Akt, as reviewed by Liao and colleagues (2019).

Known effects

• Adenylate cyclase activation — potent cAMP elevation via PAC1R; ~1,000-fold more active than VIP
• Neuroprotection — activation of PI3K/Akt and CREB pathways supports neuronal survival in preclinical models
• Stress sensitization — upregulates HPA axis reactivity; amplifies fear response via amygdala PAC1R
• Migraine induction — provokes migraine-like headache in susceptible individuals; mechanism implicates mast cell degranulation and vasodilation
• PAC1R splice-isoform modulation — differentially activates hip and hop splice variants of PAC1R; tool for investigating isoform-specific signaling (Blechman and colleagues, Frontiers in Endocrinology, 2013)
• Sex hormone interaction — estrogen regulation of ADCYAP1R1 amplifies PACAP effects in females (King and colleagues, 2017)

Mechanism

PAC1R (gene ADCYAP1R1) is a class B GPCR whose extracellular N-terminal domain (ECD) constitutes the primary binding site for PACAP. The C-terminal portion of PACAP engages the ECD; the N-terminal region then inserts into the transmembrane bundle to activate the receptor — the canonical "two-domain binding" model common to secretin-family GPCRs. Residues His1 through Leu27 of PACAP form a continuous α-helix that protrudes from the transmembrane binding pocket; this helical structure is essential for receptor activation. PACAP-27 lacks the 11-residue C-terminal extension of PACAP-38 (residues 28–38), which accounts for its ~10-fold lower binding affinity at PAC1R but does not substantially reduce cAMP-generating potency because the receptor is spare.

Upon activation, PAC1R couples primarily to Gαs, stimulating adenylyl cyclase and elevating cAMP to activate PKA and CREB — the canonical neurotrophic and neuroprotective cascade. PAC1R additionally couples to Gαq (activating phospholipase C and raising intracellular calcium) and signals through β-arrestin-mediated MEK/ERK and PI3K/Akt pathways from endosomal compartments after receptor internalization (Liao and colleagues, 2019). The receptor undergoes extensive alternative splicing, particularly in the third intracellular loop (the "hip" and "hop" cassettes), generating isoforms with distinct signaling biases; Blechman and colleagues (2013) describe this splicing as a mechanism for fine-tuning brain activity. PACAP-27 is selectively active at PAC1R relative to VPAC1/VPAC2 at low concentrations, though it is less PAC1R-selective than PACAP-38. Conversely, PACAP-27 shows slightly higher affinity for VPAC1 (~0.23 nM) compared with PACAP-38, making it a tool for probing receptor-selective signaling contexts. A small-molecule PAC1R antagonist designed to probe neuropathic pain circuits was developed and characterized by Takasaki and colleagues (2020), reflecting the drug-discovery interest this receptor has generated.

The chicken variant stored here (Ile² instead of Ser²) retains the same core receptor pharmacology as the mammalian sequence but is useful as an evolutionary reference and as a tool in avian-model studies. The C-terminal amide present on the natural peptide is not represented in the raw sequence; Emery and colleagues (Peptides, 2016) demonstrated that C-terminal amidation is dispensable for PAC1R activity, which broadens the utility of synthetic PACAP-27 variants without amide processing.

Safety signals

No clinical safety profile exists for PACAP-27 as a standalone administered compound in humans. As a research tool peptide, it is studied at pharmacological concentrations in cellular and rodent systems. The primary safety-relevant context for the PACAP/PAC1 pathway is its role as a trigger of migraine-like headache — demonstrated for both PACAP-27 and PACAP-38 via intravenous provocation in headache-susceptible subjects. Vasodilation and dural mast cell activation are proposed mechanisms. There are no published adverse event reports from clinical administration of PACAP-27 specifically.

Regulatory status

• US: Not FDA-approved or regulated as a drug; classified as a research tool peptide.
• Research use: Commercially synthesized for laboratory use; the chicken variant is listed as distinct from the human/ovine/rat form in peptide supplier catalogs.
• Drug development: PAC1R is an active drug target; small-molecule antagonists targeting this receptor are in preclinical development for PTSD, migraine, and neuropathic pain (Takasaki and colleagues, 2020; Liao and colleagues, 2019).

Related peptides

• PACAP-38 — the full-length 38-residue form; higher PAC1R binding affinity (~10-fold vs PACAP-27); the primary form studied in PTSD and migraine provocation research
• VIP (Vasoactive Intestinal Peptide) — shares ~68% sequence identity with PACAP-27; activates VPAC1 and VPAC2 but is ~1,000-fold less potent than PACAP at PAC1R
• PACAP(6–27) — truncated antagonist fragment used to block PAC1R in functional studies; a standard pharmacological tool for probing the PACAP stress and pain circuits